KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacira BioSciences (PCRX) EBT Margin: 2010-2025

Historic EBT Margin for Pacira BioSciences (PCRX) over the last 16 years, with Sep 2025 value amounting to 5.31%.

  • Pacira BioSciences' EBT Margin rose 8768.00% to 5.31% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.84%, marking a year-over-year increase of 1374.00%. This contributed to the annual value of -9.00% for FY2024, which is 1814.00% down from last year.
  • Per Pacira BioSciences' latest filing, its EBT Margin stood at 5.31% for Q3 2025, which was up 598.60% from -1.06% recorded in Q2 2025.
  • Over the past 5 years, Pacira BioSciences' EBT Margin peaked at 22.34% during Q2 2023, and registered a low of -82.37% during Q3 2024.
  • Its 3-year average for EBT Margin is 0.36%, with a median of 8.16% in 2024.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by 9,250bps in 2024, then surged by 8,768bps in 2025.
  • Pacira BioSciences' EBT Margin (Quarterly) stood at -3.89% in 2021, then slumped by 661bps to -10.51% in 2022, then spiked by 2,911bps to 18.60% in 2023, then tumbled by 497bps to 13.63% in 2024, then soared by 8,768bps to 5.31% in 2025.
  • Its last three reported values are 5.31% in Q3 2025, -1.06% for Q2 2025, and 5.15% during Q1 2025.